{"id":81469,"date":"2018-08-08T07:42:20","date_gmt":"2018-08-08T14:42:20","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2018\/08\/samumed-in-438-million-deal-to-develop-anti-agingtherapies"},"modified":"2018-08-10T07:06:19","modified_gmt":"2018-08-10T14:06:19","slug":"samumed-in-438-million-deal-to-develop-anti-agingtherapies","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2018\/08\/samumed-in-438-million-deal-to-develop-anti-agingtherapies","title":{"rendered":"Samumed in $438 Million Deal to Develop Anti-agingTherapies"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/samumed-in-438-million-deal-to-develop-anti-agingtherapies.jpg\"><\/a><\/p>\n<p>Today, we were pleased to hear that Samumed, a San Diego-based biotech company working on regenerative medicine, has just <a href=\"https:\/\/www.samumed.com\/medium\/image\/samumed-closes-on-438-million-in-equity-financing_371\/view.aspx\">raised $438 million<\/a> towards developing anti-aging therapies.<\/p>\n<blockquote><p>SAN DIEGO \u2013 August 6, 2018 \u2013 Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised to date to more than $650 million. The pre-money valuation for the round was $12 billion.<\/p>\n<p>\u201cWe appreciate the strong support from our investors,\u201d said Osman Kibar, Ph.D., Chief Executive Officer of Samumed, \u201cand we are now in a fortunate position to both move our later stage programs to commercialization, as well as expand on our earlier stage science and clinical portfolio.\u201d<\/p><\/blockquote>\n<p><!-- Link: <a href=\"https:\/\/www.leafscience.org\/samumed\/\">https:\/\/www.leafscience.org\/samumed\/<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Today, we were pleased to hear that Samumed, a San Diego-based biotech company working on regenerative medicine, has just raised $438 million towards developing anti-aging therapies. SAN DIEGO \u2013 August 6, 2018 \u2013 Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised [\u2026]<\/p>\n","protected":false},"author":370,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269],"tags":[],"class_list":["post-81469","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/81469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/370"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=81469"}],"version-history":[{"count":1,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/81469\/revisions"}],"predecessor-version":[{"id":81540,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/81469\/revisions\/81540"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=81469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=81469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=81469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}